SOCIETAL COSTS ASSOCIATED WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN THE UNITED STATES
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
PURPOSE: The purpose of this study was to use a cross-sectional prevalence-based health care economic survey to ascertain the annual, incremental, societal ophthalmic costs associated with neovascular age-related macular degeneration. METHODS: Consecutive patients (n = 200) with neovascular age-related macular degeneration were studied. A Control Cohort included patients with good (20/20-20/25) vision, while Study Cohort vision levels included Subcohort 1: 20/30 to 20/50, Subcohort 2: 20/60 to 20/100, Subcohort 3: 20/200 to 20/400, and Subcohort 4: 20/800 to no light perception. An interviewer-administered, standardized, written survey assessed 1) direct ophthalmic medical, 2) direct nonophthalmic medical, 3) direct nonmedical, and 4) indirect medical costs accrued due solely to neovascular age-related macular degeneration. RESULTS: The mean annual societal cost for the Control Cohort was $6,116 and for the Study Cohort averaged $39,910 (P < 0.001). Study Subcohort 1 costs averaged $20,339, while Subcohort 4 costs averaged $82,984. Direct ophthalmic medical costs comprised 17.9% of Study Cohort societal ophthalmic costs, versus 74.1% of Control Cohort societal ophthalmic costs (P < 0.001) and 10.4% of 20/800 to no light perception subcohort costs. Direct nonmedical costs, primarily caregiver, comprised 67.1% of Study Cohort societal ophthalmic costs, versus 21.3% ($1,302/$6,116) of Control Cohort costs (P < 0.001) and 74.1% of 20/800 to no light perception subcohort costs. CONCLUSION: Total societal ophthalmic costs associated with neovascular age-related macular degeneration dramatically increase as vision in the better-seeing eye decreases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Recommendations for Reporting Cost-effectiveness Analyses
Siegel, J. E. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03540160061034 · Cited by 1,147 · cited 1×
“Admission costs to new self-care and/or assisted care residences due to visual disability or anticipation of such were amortized at 3% per year with net present value analysis over a patient’s life expectancy, as were moving costs.(36,37) Net present value analysis integrated time already lived in the residence, as we…”
BackgroundCruess, A. F., Zlateva, G., Xu, X., Soubrane, G., Pauleikhoff, D., Lotery, A., Mones, J., Buggage, R., Schaefer, C., Knight, T., et al. (2008) · PharmacoEconomics · doi:10.2165/00019053-200826010-00006 · Cited by 126
Ke, K. M. (2010) · The European Journal of Health Economics · doi:10.1007/s10198-009-0207-9 · Cited by 25
Cited by
The economics of vision impairment and its leading causes: A systematic review
Marques, A. P., Ramke, J., Cairns, J., Butt, T., Zhang, J. H., Jones, I., Jovic, M., Nandakumar, A., Faal, H., Taylor, H., et al. (2022) · eClinicalMedicine · doi:10.1016/j.eclinm.2022.101354 · Cited by 137
Efficacy and Safety of Abicipar in Neovascular Age-Related Macular Degeneration
Kunimoto, D., Yoon, Y. H., Wykoff, C. C., Chang, A., Khurana, R. N., Maturi, R. K., Agostini, H., Souied, E., Chow, D. R., Lotery, A. J., et al. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2020.03.035 · Cited by 91
Cost-effectiveness of Artificial Intelligence–Based Retinopathy of Prematurity Screening
Morrison, S. L., Dukhovny, D., Chan, R. V. P., Chiang, M. F., & Campbell, J. P. (2022) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2022.0223 · Cited by 61
Patel, P. J., Ziemssen, F., Ng, E., Muthutantri, A., Silverman, D., Tschosik, E. A., & Cantrell, R. A. (2020) · Clinical Ophthalmology · doi:10.2147/opth.s226425 · Cited by 61
Metadata
- Authors
- Brown, M. M., Brown, G. C., Lieske, H. B., Tran, I., Turpcu, A., & Colman, S.
- Venue
- Retina
- Published
- 2016-02
- Volume
- 36
- Issue
- 2
- Pages
- 285-298
- ISSN
- 0275-004X (ISSN-L)
- OpenAlex
- W2324562749
- Cited by
- 59
- References
- 3
- FWCI
- 2.03
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: SOCIETAL COSTS ASSOCIATED WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN THE UNITED STATES. https://app.cochat.ai/papers/10.1097/iae.0000000000000717
- The paper
- Brown, M. M., Brown, G. C., Lieske, H. B., Tran, I., Turpcu, A., & Colman, S. (2016). SOCIETAL COSTS ASSOCIATED WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN THE UNITED STATES. Retina. https://doi.org/10.1097/iae.0000000000000717
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.